Authors
Zixin Shu, Kai Chang, Yana Zhou, Chaoan Peng, Xugui Li, Wei Cai, Li Wei, Qiguang Zheng, Haoyu Tian, Jianan Xia, Kuo Yang, Ning Wang, Jifen Liu, Xiaojun Min, Dengying Yan, Jing Sun, Huan Wu, Xiaomeng Li, Yi Zheng, Zecong Yu, Xi Lu, Yuxia Yang, Ting Jia, Jinghui Ji, Qunzheng Zou, Yinyan Wang, Minzhong Xiao, Qing Zhang, Yajuan Xiong, Feng Sun, Qiang Zhu, Xingxing Jiang, Guodong Wang, Sydney Chi-Wai Tang, Junhua Zhang, Xiuyang Li, Nevin Zhang, Boli Zhang, Xiaolin Tong, Baoyan Liu, Xuezhong Zhou, Kam Wa Chan, Xiaodong Li
Publication date
2021/3/5
Journal
The American Journal of Chinese Medicine
Volume
49
Issue
03
Pages
543-575
Publisher
World Scientific Publishing Company
Description
Chinese medicine (CM) was extensively used to treat COVID-19 in China. We aimed to evaluate the real-world effectiveness of add-on semi-individualized CM during the outbreak. A retrospective cohort of 1788 adult confirmed COVID-19 patients were recruited from 2235 consecutive linked records retrieved from five hospitals in Wuhan during 15 January to 13 March 2020. The mortality of add-on semi-individualized CM users and non-users was compared by inverse probability weighted hazard ratio (HR) and by propensity score matching. Change of biomarkers was compared between groups, and the frequency of CMs used was analyzed. Subgroup analysis was performed to stratify disease severity and dose of CM exposure. The crude mortality was 3.8% in the semi-individualized CM user group and 17.0% among the non-users. Add-on CM was associated with a mortality reduction of 58% (HR = 0.42, 95% CI: 0.23 to 0 …
Scholar articles
Z Shu, K Chang, Y Zhou, C Peng, X Li, W Cai, L Wei… - The American Journal of Chinese Medicine, 2021